{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T11:28:42Z","timestamp":1784633322350,"version":"3.55.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100001809","name":"the National Nature Science Foundation of China","doi-asserted-by":"crossref","award":["81572665"],"award-info":[{"award-number":["81572665"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"International Cooperation Project of Science and Technology Plan of Guangdong Province","award":["2014A050503033"],"award-info":[{"award-number":["2014A050503033"]}]},{"name":"International Cooperation Project of Science and Technology Plan of Guangdong Province","award":["2016A050502011"],"award-info":[{"award-number":["2016A050502011"]}]},{"name":"Science and Technology Plan Project of Guangdong Province","award":["2013B021800141"],"award-info":[{"award-number":["2013B021800141"]}]},{"name":"Foundation of Science and Technology Bureau of Guangzhou City","award":["2014Y2-00179"],"award-info":[{"award-number":["2014Y2-00179"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12885-017-3080-4","type":"journal-article","created":{"date-parts":[[2017,2,15]],"date-time":"2017-02-15T12:02:55Z","timestamp":1487160175000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Safety and efficacy of lobaplatin combined with 5-fluorouracil as first-line induction chemotherapy followed by lobaplatin-radiotherapy in locally advanced nasopharyngeal carcinoma: preliminary results of a prospective phase II trial"],"prefix":"10.1186","volume":"17","author":[{"given":"Liang-Ru","family":"Ke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Xiong","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Ze","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Jun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Hui","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Fang","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Qun","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,2,15]]},"reference":[{"key":"3080_CR1","doi-asserted-by":"crossref","first-page":"114","DOI":"10.5732\/cjc.010.10377","volume":"30","author":"SM Cao","year":"2011","unstructured":"Cao SM, Simons MJ, Qian CN. The prevalence and prevention of nasopharyngeal carcinoma in China. Chin J Cancer. 2011;30:114\u201319.","journal-title":"Chin J Cancer"},{"key":"3080_CR2","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1200\/JCO.2008.19.9109","volume":"27","author":"N Lee","year":"2009","unstructured":"Lee N, Harris J, Garden AS, Straube W, Glisson B, Xia P, Bosch W, Morrison WH, Quivey J, Thorstad W, Jones C, Ang KK. Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225. J Clin Oncol. 2009;27:3684\u201390.","journal-title":"J Clin Oncol"},{"key":"3080_CR3","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1200\/JCO.1998.16.4.1310","volume":"16","author":"M Al-Sarraf","year":"1998","unstructured":"Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, Forastiere AA, Adams G, Sakr WA, Schuller DE, Ensley JF. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J CLIN ONCOL. 1998;16:1310\u201317.","journal-title":"J CLIN ONCOL"},{"key":"3080_CR4","first-page":"1328","volume":"121","author":"AW Lee","year":"2015","unstructured":"Lee AW, Ngan RK, Tung SY, Cheng A, Kwong DL, Lu TX, Chan AT, Chan LL, Yiu H, Ng WT, Wong F, Yuen KT, Yau S, Cheung FY, Chan OS, Choi H, Chappell R. Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fractionation in patients with locoregionally advanced nasopharyngeal carcinoma. Cancer Am Cancer Soc. 2015;121:1328\u201338.","journal-title":"Cancer Am Cancer Soc"},{"key":"3080_CR5","first-page":"4111","volume":"119","author":"L Kong","year":"2013","unstructured":"Kong L, Hu C, Niu X, Zhang Y, Guo Y, Tham IW, Lu JJ. Neoadjuvant chemotherapy followed by concurrent chemoradiation for locoregionally advanced nasopharyngeal carcinoma: interim results from 2 prospective phase 2 clinical trials. CANCER-AM CANCER SOC. 2013;119:4111\u201318.","journal-title":"CANCER-AM CANCER SOC"},{"key":"3080_CR6","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S1470-2045(11)70320-5","volume":"13","author":"L Chen","year":"2012","unstructured":"Chen L, Hu CS, Chen XZ, Hu GQ, Cheng ZB, Sun Y, Li WX, Chen YY, Xie FY, Liang SB, Chen Y, Xu TT, Li B, Long GX, Wang SY, Zheng BM, Guo Y, Sun Y, Mao YP, Tang LL, Chen YM, Liu MZ, Ma J. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Lancet Oncol. 2012;13:163\u201371.","journal-title":"Lancet Oncol"},{"key":"3080_CR7","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/annonc\/mdr116","volume":"23","author":"G Fountzilas","year":"2012","unstructured":"Fountzilas G, Ciuleanu E, Bobos M, Kalogera-Fountzila A, Eleftheraki AG, Karayannopoulou G, Zaramboukas T, Nikolaou A, Markou K, Resiga L, Dionysopoulos D, Samantas E, Athanassiou H, Misailidou D, Skarlos D, Ciuleanu T. Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma: a randomized phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation. Ann Oncol. 2012;23:427\u201335.","journal-title":"Ann Oncol"},{"key":"3080_CR8","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.2008.18.1545","volume":"27","author":"EP Hui","year":"2009","unstructured":"Hui EP, Ma BB, Leung SF, King AD, Mo F, Kam MK, Yu BK, Chiu SK, Kwan WH, Ho R, Chan I, Ahuja AT, Zee BC, Chan AT. Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J CLIN ONCOL. 2009;27:242\u201349.","journal-title":"J CLIN ONCOL"},{"key":"3080_CR9","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/0360-3016(95)00218-N","volume":"33","author":"AT Chan","year":"1995","unstructured":"Chan AT, Teo PM, Leung TW, Leung SF, Lee WY, Yeo W, Choi PH, Johnson PJ. A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 1995;33:569\u201377.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3080_CR10","doi-asserted-by":"crossref","unstructured":"International NCSG: Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in stage IV (\u2265N2, M0) undifferentiated nasopharyngeal carcinoma: A positive effect on progression-free survival. Int J Radiat Oncol Biol Phys. 1996;35:463\u20139.","DOI":"10.1016\/S0360-3016(96)80007-1"},{"key":"3080_CR11","first-page":"2270","volume":"83","author":"DT Chua","year":"1998","unstructured":"Chua DT, Sham JS, Choy D, Lorvidhaya V, Sumitsawan Y, Thongprasert S, Vootiprux V, Cheirsilpa A, Azhar T, Reksodiputro AH. Preliminary report of the Asian-Oceanian Clinical Oncology Association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma. Asian-Oceanian Clinical Oncology Association Nasopharynx Cancer Study Group. CANCER-AM CANCER SOC. 1998;83:2270\u201383.","journal-title":"CANCER-AM CANCER SOC"},{"key":"3080_CR12","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1200\/JCO.2001.19.5.1350","volume":"19","author":"J Ma","year":"2001","unstructured":"Ma J, Mai HQ, Hong MH, Min HQ, Mao ZD, Cui NJ, Lu TX, Mo HY. Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. J CLIN ONCOL. 2001;19:1350\u201357.","journal-title":"J CLIN ONCOL"},{"key":"3080_CR13","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1200\/JCO.2005.12.081","volume":"23","author":"DT Chua","year":"2005","unstructured":"Chua DT, Ma J, Sham JS, Mai HQ, Choy DT, Hong MH, Lu TX, Min HQ. Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: a pooled data analysis of two phase III trials. J CLIN ONCOL. 2005;23:1118\u201324.","journal-title":"J CLIN ONCOL"},{"key":"3080_CR14","first-page":"2217","volume":"94","author":"M Hareyama","year":"2002","unstructured":"Hareyama M, Sakata K, Shirato H, Nishioka T, Nishio M, Suzuki K, Saitoh A, Oouchi A, Fukuda S, Himi T. A prospective, randomized trial comparing neoadjuvant chemotherapy with radiotherapy alone in patients with advanced nasopharyngeal carcinoma. CANCER-AM CANCER SOC. 2002;94:2217\u201323.","journal-title":"CANCER-AM CANCER SOC"},{"key":"3080_CR15","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/S1470-2045(16)30410-7","volume":"17","author":"Y Sun","year":"2016","unstructured":"Sun Y, Li WF, Chen NY, Zhang N, Hu GQ, Xie FY, Sun Y, Chen XZ, Li JG, Zhu XD, Hu CS, Xu XY, Chen YY, Hu WH, Guo L, Mo HY, Chen L, Mao YP, Sun R, Ai P, Liang SB, Long GX, Zheng BM, Feng XL, Gong XC, Li L, Shen CY, Xu JY, Guo Y, Chen YM, Zhang F, Lin L, Tang LL, Liu MZ, Ma J. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol. 2016;17:1509\u201320.","journal-title":"Lancet Oncol"},{"key":"3080_CR16","first-page":"2230","volume":"119","author":"Y Chen","year":"2013","unstructured":"Chen Y, Sun Y, Liang SB, Zong JF, Li WF, Chen M, Chen L, Mao YP, Tang LL, Guo Y, Lin AH, Liu MZ, Ma J. Progress report of a randomized trial comparing long-term survival and late toxicity of concurrent chemoradiotherapy with adjuvant chemotherapy versus radiotherapy alone in patients with stage III to IVB nasopharyngeal carcinoma from endemic regions of China. CANCER-AM CANCER SOC. 2013;119:2230\u201338.","journal-title":"CANCER-AM CANCER SOC"},{"key":"3080_CR17","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/ijc.27638","volume":"132","author":"MF Gu","year":"2013","unstructured":"Gu MF, Liu LZ, He LJ, Yuan WX, Zhang R, Luo GY, Xu GL, Zhang HM, Yan CX, Li JJ. Sequential chemoradiotherapy with gemcitabine and cisplatin for locoregionally advanced nasopharyngeal carcinoma. Int J Cancer. 2013;132:215\u201323.","journal-title":"Int J Cancer"},{"key":"3080_CR18","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s00280-016-2976-z","volume":"77","author":"S Dilruba","year":"2016","unstructured":"Dilruba S, Kalayda GV. Platinum-based drugs: past, present and future. Cancer Chemother Pharmacol. 2016;77:1103\u201324.","journal-title":"Cancer Chemother Pharmacol"},{"key":"3080_CR19","first-page":"2349","volume":"5","author":"J Welink","year":"1999","unstructured":"Welink J, Boven E, Vermorken JB, Gall HE, van der Vijgh WJ. Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function. Clin Cancer Res. 1999;5:2349\u201358.","journal-title":"Clin Cancer Res"},{"key":"3080_CR20","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1517\/13543784.10.1.119","volume":"10","author":"MJ McKeage","year":"2001","unstructured":"McKeage MJ. Lobaplatin: a new antitumour platinum drug. Expert Opin Investig Drugs. 2001;10:119\u201328.","journal-title":"Expert Opin Investig Drugs"},{"key":"3080_CR21","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/annonc\/mdl331","volume":"18","author":"FG Perabo","year":"2007","unstructured":"Perabo FG, Muller SC. New agents for treatment of advanced transitional cell carcinoma. Ann Oncol. 2007;18:835\u201343.","journal-title":"Ann Oncol"},{"key":"3080_CR22","first-page":"1131","volume":"39","author":"X Li","year":"2014","unstructured":"Li X, Li Y. Clinical study on chemotherapy of lobaplatin combined with docetaxel in patients with relapsed ovarian cancer. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2014;39:1131\u201336.","journal-title":"Zhong Nan Da Xue Xue Bao Yi Xue Ban"},{"key":"3080_CR23","doi-asserted-by":"crossref","first-page":"4629","DOI":"10.7314\/APJCP.2015.16.11.4629","volume":"16","author":"WP Li","year":"2015","unstructured":"Li WP, Liu H, Chen L, Yao YQ, Zhao EF. A clinical comparison of lobaplatin or cisplatin with mitomycine and vincristine in treating patients with cervical squamous carcinoma. Asian Pac J Cancer Prev. 2015;16:4629\u201331.","journal-title":"Asian Pac J Cancer Prev"},{"key":"3080_CR24","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.oraloncology.2014.04.007","volume":"50","author":"GX Long","year":"2014","unstructured":"Long GX, Lin JW, Liu DB, Zhou XY, Yuan XL, Hu GY, Mei Q, Hu GQ. Single-arm, multi-centre phase II study of lobaplatin combined with docetaxel for recurrent and metastatic nasopharyngeal carcinoma patients. Oral Oncol. 2014;50:717\u201320.","journal-title":"Oral Oncol"},{"key":"3080_CR25","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2003.06.158","volume":"21","author":"JC Lin","year":"2003","unstructured":"Lin JC, Jan JS, Hsu CY, Liang WM, Jiang RS, Wang WY. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J CLIN ONCOL. 2003;21:631\u201337.","journal-title":"J CLIN ONCOL"},{"key":"3080_CR26","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.radonc.2009.02.005","volume":"92","author":"M Airoldi","year":"2009","unstructured":"Airoldi M, Gabriele AM, Garzaro M, Raimondo L, Condello C, Beatrice F, Pecorari G, Giordano C. Induction chemotherapy with cisplatin and epirubicin followed by radiotherapy and concurrent cisplatin in locally advanced nasopharyngeal carcinoma observed in a non-endemic population. Radiother Oncol. 2009;92:105\u201310.","journal-title":"Radiother Oncol"},{"key":"3080_CR27","doi-asserted-by":"crossref","first-page":"4305","DOI":"10.1200\/JCO.2001.19.23.4305","volume":"19","author":"RL Hong","year":"2001","unstructured":"Hong RL, Ting LL, Ko JY, Hsu MM, Sheen TS, Lou PJ, Wang CC, Chung NN, Lui LT. Induction chemotherapy with mitomycin, epirubicin, cisplatin, fluorouracil, and leucovorin followed by radiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma. J CLIN ONCOL. 2001;19:4305\u201313.","journal-title":"J CLIN ONCOL"},{"key":"3080_CR28","doi-asserted-by":"crossref","first-page":"5957","DOI":"10.7314\/APJCP.2015.16.14.5957","volume":"16","author":"JQ Wang","year":"2015","unstructured":"Wang JQ, Wang T, Shi F, Yang YY, Su J, Chai YL, Liu Z. A Randomized Controlled Trial Comparing Clinical Outcomes and Toxicity of Lobaplatin- Versus Cisplatin-Based Concurrent Chemotherapy Plus Radiotherapy and High-Dose-Rate Brachytherapy for FIGO Stage II and III Cervical Cancer. Asian Pac J Cancer Prev. 2015;16:5957\u201361.","journal-title":"Asian Pac J Cancer Prev"},{"key":"3080_CR29","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/imj.12773","volume":"45","author":"JS Yang","year":"2015","unstructured":"Yang JS, Wang T, Qiu MQ, Li QL. Comparison of efficacy and toxicity profiles between paclitaxel\/lobapoatin- and cisplatin\/5-fluorouracil-based concurrent chemoradiotherapy of advanced inoperable oesophageal cancer. Intern Med J. 2015;45:757\u201361.","journal-title":"Intern Med J"},{"key":"3080_CR30","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1097\/CAD.0000000000000370","volume":"27","author":"S Zhang","year":"2016","unstructured":"Zhang S, Chen J, Yang S, Lin S. An open-label, single-arm phase II clinical study of docetaxel plus lobaplatin for Chinese patients with pulmonary and hepatic metastasis of nasopharyngeal carcinoma. Anticancer Drugs. 2016;27:685\u201388.","journal-title":"Anticancer Drugs"},{"key":"3080_CR31","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1159\/000151363","volume":"74","author":"D Ferrari","year":"2008","unstructured":"Ferrari D, Chiesa F, Codeca C, Calabrese L, Jereczek-Fossa BA, Alterio D, Fiore J, Luciani A, Floriani I, Orecchia R, Foa P. Locoregionally advanced nasopharyngeal carcinoma: induction chemotherapy with cisplatin and 5-fluorouracil followed by radiotherapy and concurrent cisplatin: a phase II study. Oncology Basel. 2008;74:158\u201366.","journal-title":"Oncology Basel"},{"key":"3080_CR32","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s13014-015-0472-y","volume":"10","author":"AP Songthong","year":"2015","unstructured":"Songthong AP, Kannarunimit D, Chakkabat C, Lertbutsayanukul C. A randomized phase II\/III study of adverse events between sequential (SEQ) versus simultaneous integrated boost (SIB) intensity modulated radiation therapy (IMRT) in nasopharyngeal carcinoma; preliminary result on acute adverse events. Radiat Oncol. 2015;10:166.","journal-title":"Radiat Oncol"},{"key":"3080_CR33","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/clpt.1981.91","volume":"29","author":"KJ Himmelstein","year":"1981","unstructured":"Himmelstein KJ, Patton TF, Belt RJ, Taylor S, Repta AJ, Sternson LA. Clinical kinetics on intact cisplatin and some related species. Clin Pharmacol Ther. 1981;29:658\u201364.","journal-title":"Clin Pharmacol Ther"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-017-3080-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T18:21:58Z","timestamp":1568830918000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-017-3080-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,15]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["3080"],"URL":"https:\/\/doi.org\/10.1186\/s12885-017-3080-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,15]]},"article-number":"134"}}